Metastatic Prostate Cancer Prognosis Calculator - Life Expectancy From Gleason, BMI, and Metastases

The metastatic prostate cancer prognosis calculator is an informational review tool that estimates years of life remaining and 5- and 10-year survival for a person who has been diagnosed with prostate cancer, using a published actuarial baseline, the Gleason score, the presence of distant metastases, body mass index, smoking status, and self-rated health.

• • Pre-appointment context: helps a patient or caregiver bring a structured estimate to a urology or oncology visit alongside the biopsy and imaging report.
• • Treatment-decision support: lets a person compare how a Gleason upgrade, weight loss, or quitting smoking shifts the projected years of life remaining.
• • Caregiver planning: summarizes how distant metastases or a Gleason 9 cancer change the time horizon for family planning and palliative care.
• • Reading clinical literature: puts a 31% five-year survival statistic into a personal frame so published studies are easier to interpret.

Prostate cancer is the second most commonly diagnosed cancer in men worldwide, and most patients survive at least ten years. The numbers change quickly once the cancer spreads outside the pelvis, which is why metastatic prognosis is treated separately from localized disease.

The calculator does not diagnose prostate cancer, replace an oncologist's assessment, or model individual treatment response. It produces a structured estimate from the user's inputs so the numbers in clinic notes and journal articles can be put into a personal context.

Pair the prognosis estimate with the PSA Doubling Time Calculator to see whether the tumor marker is changing quickly or staying stable.

The model starts from a US-male baseline annual mortality rate, adds a Gleason-specific cancer mortality rate, and multiplies the combined rate by published relative risks for distant metastases, current smoking, body mass index of 30 or higher, and self-rated health. Survival is integrated year by year to age 110 to produce life expectancy, 5-year survival, and 10-year survival.

• Age: Sets the baseline mortality rate from the Social Security 2020 actuarial life table for US males.
• Height and weight: Used to compute body mass index; BMI of 30 or higher adds the obesity hazard multiplier.
• Gleason score: Pathology grade from the biopsy; bands 2-4, 5-6, 7, and 8-10 each have a published cancer-specific mortality rate per 1000 person-years.
• Custom mortality: Optional user-entered cancer-specific mortality rate per 1000 person-years used when Gleason is set to custom.
• Distant metastases: Yes or no; doubles the cancer-specific mortality rate to reflect the higher hazard in distant-stage disease.
• Health level: Self-rated health compared to age peers; scales the baseline non-cancer mortality rate by 0.85, 1.00, or 1.50.
• Current smoker: Yes or no; multiplies the cancer-specific mortality rate by the Huncharek 2010 relative risk of 1.14.

The model is intentionally narrow. It does not adjust for ethnicity, family history, prior treatment, response to androgen deprivation therapy, or new therapies such as PARP inhibitors, so the result is reported as informational rather than a clinical prediction.

Custom mortality overrides the Gleason band. A clinician with a published nomogram can enter that rate directly, and the rest of the model still applies the BMI, smoking, metastases, and health-level adjustments.

According to American Cancer Society: Prostate Cancer Key Statistics, the 5-year relative survival for distant-stage prostate cancer is about 31%.

According to Albertsen, Hanley, Fine 2005, JAMA 20-year outcomes, Gleason-stratified prostate cancer mortality runs about 6, 14, 30, and 121 deaths per 1000 person-years for Gleason bands 2-4, 5-6, 7, and 8-10 in a 20-year follow-up cohort.

The PSA Density Calculator summarizes the absolute PSA level relative to gland size in a related prostate workflow.

These four ideas explain why the model is built the way it is, and what each input is doing inside the calculation.

Together these four ideas mean the model is sensitive to both the underlying cancer biology and the things a person can change, like smoking and weight. They also explain why a Gleason 6 result in a 70-year-old looks more favorable than the same Gleason 6 in a 90-year-old with poor health.

The same stacking idea of baseline plus relative-risk multipliers shows up in the Breast Cancer Risk Calculator, which uses a SEER baseline with the Gail 1989 relative risks.

Each input feeds a different part of the model. Enter the values from the same clinical record for the result to be meaningful.

1. 1 Enter the current age: Type the patient's age in years, between 35 and 95.
2. 2 Enter height and weight: Type the height in centimeters and the weight in kilograms; the calculator computes BMI and applies the obesity multiplier at BMI 30 or higher.
3. 3 Select the Gleason score band: Pick the Gleason band that matches the biopsy report, or choose custom to enter a cancer-specific mortality rate per 1000 person-years.
4. 4 Indicate distant metastases: Set distant metastases to yes if imaging has shown the cancer spread outside the pelvis; the calculator then doubles the cancer-specific rate.
5. 5 Rate the health level: Choose good, average, or poor compared to age peers; this scales the baseline non-cancer mortality rate.
6. 6 Indicate current smoking: Set current smoker to yes if the patient is a current smoker; the calculator multiplies the cancer-specific rate by 1.14.

A clinician enters age 70, height 178 cm, weight 76 kg, Gleason 8-10, distant metastases yes, average health, non-smoker. The result panel shows about 4.4 years of life remaining and a 5-year survival of about 36%, which can be discussed alongside the imaging and treatment plan.

The calculator turns a handful of clinical inputs into a single structured estimate that can be used in several real decisions.

• • Puts a Gleason score in time-frame terms: Converts a pathology grade into years of life remaining and 5- or 10-year survival so the report number has a personal meaning.
• • Shows the impact of modifiable risks: Re-running after a BMI change or a smoking-cessation step shows how those choices change the time horizon.
• • Helps clinic conversations: Brings a structured estimate to an appointment so the conversation focuses on what the value means, not on recalculating the math.
• • Pairs with other prostate tools: Works alongside the PSA Density Calculator and the PSA Doubling Time Calculator so the absolute level, density, and rate of change can be reviewed together.
• • Custom mortality option: Lets a clinician plug in a mortality rate from a nomogram when the Gleason band is too coarse.
• • Audit-friendly outputs: Reports the inputs, the combined annual mortality rate, and the integrated survival so the numbers can be checked.

The benefits above are practical rather than diagnostic. They describe how the calculator fits into a clinical workflow, not whether it can rule in or rule out treatment.

For someone weighing whether to quit, the Smoking Recovery Calculator gives a year-by-year picture of life-years typically recovered after stopping, complementing the modifiable-risk line above.

The estimate is sensitive to both the inputs and the assumptions in the model. The factors below are the most common reasons two estimates from the same calculator can disagree.

• • The calculator does not adjust for ethnicity, family history, prior treatment, response to androgen deprivation therapy, or newer therapies such as PARP inhibitors.
• • The Gleason bands are coarse; a Gleason 4+3 cancer is grouped with Gleason 3+4 in the same Gleason 7 band.
• • The metastases flag is binary and does not distinguish bone-only, lymph-node-only, or visceral metastases.
• • The model is built from US actuarial data; estimates for patients in other countries will be biased.

These limitations are why the result panel is labeled as informational and the page includes a clear disclaimer that the estimate does not replace an oncologist's assessment.

According to Zhang et al. 2015, Oncology Letters (impact of obesity on prostate cancer mortality), obesity is associated with a relative risk of 1.24 for prostate cancer mortality in a meta-analysis of 17 cohort studies.

The EORTC bladder cancer risk calculator uses a similar study cohort and summary of risk factors for bladder cancer.